Landscape Capital Management L.L.C. Invests $1 Million in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)

Landscape Capital Management L.L.C. acquired a new stake in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) in the third quarter, Holdings Channel reports. The fund acquired 8,684 shares of the company’s stock, valued at approximately $1,001,000.

Other institutional investors have also recently added to or reduced their stakes in the company. O Shaughnessy Asset Management LLC boosted its holdings in shares of Neurocrine Biosciences by 16.8% during the first quarter. O Shaughnessy Asset Management LLC now owns 3,695 shares of the company’s stock valued at $510,000 after acquiring an additional 531 shares during the period. UniSuper Management Pty Ltd lifted its position in Neurocrine Biosciences by 100.0% in the 1st quarter. UniSuper Management Pty Ltd now owns 1,400 shares of the company’s stock valued at $193,000 after purchasing an additional 700 shares during the last quarter. EntryPoint Capital LLC boosted its stake in Neurocrine Biosciences by 76.1% during the 1st quarter. EntryPoint Capital LLC now owns 516 shares of the company’s stock valued at $71,000 after purchasing an additional 223 shares during the period. Canada Pension Plan Investment Board grew its position in Neurocrine Biosciences by 186.1% in the 1st quarter. Canada Pension Plan Investment Board now owns 188,549 shares of the company’s stock worth $26,005,000 after purchasing an additional 122,649 shares during the last quarter. Finally, Truvestments Capital LLC increased its stake in shares of Neurocrine Biosciences by 111.2% in the first quarter. Truvestments Capital LLC now owns 566 shares of the company’s stock valued at $78,000 after purchasing an additional 298 shares during the period. 92.59% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

NBIX has been the subject of several analyst reports. JPMorgan Chase & Co. boosted their price objective on Neurocrine Biosciences from $173.00 to $181.00 and gave the stock an “overweight” rating in a research report on Wednesday, August 7th. BMO Capital Markets reduced their price target on Neurocrine Biosciences from $128.00 to $114.00 and set a “market perform” rating for the company in a research report on Thursday, October 17th. Barclays lowered their price target on Neurocrine Biosciences from $180.00 to $160.00 and set an “overweight” rating on the stock in a report on Monday, September 9th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $155.00 price objective on shares of Neurocrine Biosciences in a report on Monday, September 16th. Finally, StockNews.com cut shares of Neurocrine Biosciences from a “strong-buy” rating to a “buy” rating in a research note on Friday, November 1st. Five analysts have rated the stock with a hold rating, nineteen have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, Neurocrine Biosciences presently has a consensus rating of “Moderate Buy” and an average price target of $163.91.

Neurocrine Biosciences Trading Up 0.5 %

Shares of NBIX opened at $125.65 on Friday. The business’s 50-day moving average price is $118.55 and its 200 day moving average price is $132.13. The stock has a market capitalization of $12.72 billion, a P/E ratio of 33.69 and a beta of 0.35. Neurocrine Biosciences, Inc. has a 1-year low of $110.52 and a 1-year high of $157.98.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.